Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | PEPD | P12955 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815611 | 0.82 | CFTR (0.49) | MKNK2MAPTTP53HDAC6HDAC1 | |
| SCHEMBL5112369 | 0.75 | KDR (0.55) | HDAC6HDAC1AURKAKDRAURKB | |
| SCHEMBL1408354 | 0.75 | QPCT (0.47) | MKNK2MAPTHDAC6HDAC1TBXAS1 | |
| SCHEMBL680855 | 0.74 | FGFR1 (0.56) | MKNK2ALDH1A1 | |
| SCHEMBL1408497 | 0.73 | RIPK1 (0.45) | MKNK2MAPTHDAC6HDAC1NPC1 | |
| Hydrochloric Acid SCHEMBL4456679 | 0.72 | FGFR1 (0.54) | MKNK2ALDH1A1 | |
| SCHEMBL3697841 | 0.71 | MKNK2 (0.49) | MKNK2HDAC6HDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL467133 | 0.71 | MKNK2 (0.47) | MKNK2HDAC6HDAC1ALDH1A1FDPS | |
| SCHEMBL27337608 | 0.70 | HDAC1 (0.42) | MKNK2HDAC6HDAC1ALDH1A1FDPS | |
| SCHEMBL17187988 | 0.69 | MKNK2 (0.49) | MKNK2HDAC6HDAC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896730-B2 | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment | OSI Pharmaceuticals, LLC (US) | 2018-02-20 | — | — | US | disclosed |
| EP-2702173-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | OSI Pharmaceuticals, LLC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057352-A1 | METHODS FOR THE IDENTIFICATION OF AGENTS THAT INHIBIT MESENCHYMAL-LIKE TUMOR CELLS OR THEIR FORMATION | OSI PHARMACEUTICALS LLC (US) | 2014-02-27 | — | — | US | disclosed |
| US-8642834-B2 | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | OSI Pharmaceuticals, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2013152252-A1 | COMBINATION ANTI-CANCER THERAPY | OSI Pharmaceuticals, LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130210026-A1 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS | OSI Pharmaceuticals, LLC | 2013-08-15 | — | — | US | disclosed |
| US-8465912-B2 | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | OSI Pharmaceuticals, LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-8377636-B2 | Biological markers predictive of anti-cancer response to kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120302572-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | AVEO PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012149014-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | OSI Pharmaceuticals, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2009111067-A9 | METHODS FOR THE IDENTIFICATION OF AGENTS THAT INHIBIT MESENCHYMAL -LIKE TUMOR CELLS OR THEIR FORMATION | OSI PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-2134860-A1 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090263397-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009111067-A2 | METHODS FOR THE IDENTIFICATION OF AGENTS THAT INHIBIT MESENCHYMAL -LIKE TUMOR CELLS OR THEIR FORMATION | OSI PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226396-A1 | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | HALEY JOHN D | 2009-09-10 | — | — | US | disclosed |
| WO-2009008992-A2 | COMBINATION ANTI-CANCER THERAPY COMPRISING AN INHIBITOR OF BOTH MTORC1 AND MT0RC2 | OSI PHARMACEUTICALS INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009009016-A1 | COMBINATION ANTI-CANCER THERAPY | OSI PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080312260-A1 | Biological markers predictive of anti-cancer response to kinase inhibitors | HALEY JOHN D | 2008-12-18 | — | — | US | disclosed |
| WO-2008127719-A1 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263397-A1 | Combination anti-cancer therapy | IGF1R, IGFBP6, IGFBP1 | MKNK2 447/4885MAPT 4658/4885TP53 125/4885 |
| US-20120302572-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | IGF1R, IGFBP1, EGFR | MKNK2 87/4885MAPT 3190/4885TP53 785/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | MKNK2 72/4885MAPT 4493/4885TP53 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.